VanEck Vectors Biotech ETF (BBH)
| Assets | $448.56M |
| NAV | $149.52 |
| Expense Ratio | 0.35% |
| PE Ratio | 14.68 |
| Shares Out | 3.00M |
| Dividend (ttm) | $0.40 |
| Dividend Yield | 0.27% |
| Ex-Dividend Date | Dec 20, 2021 |
| 1-Year Return | -25.97% |
| Volume | 41,167 |
| Open | 147.76 |
| Previous Close | 146.43 |
| Day's Range | 146.31 - 149.67 |
| 52-Week Low | 131.12 |
| 52-Week High | 222.22 |
| Beta | 0.86 |
| Holdings | 26 |
| Inception Date | Dec 20, 2011 |
About BBH
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Top 10 Holdings
64.33% of assets| Name | Symbol | Weight |
|---|---|---|
| Amgen | AMGN | 13.36% |
| Gilead Sciences | GILD | 7.86% |
| Vertex Pharmaceuticals | VRTX | 7.56% |
| Regeneron Pharmaceuticals | REGN | 6.13% |
| Moderna | MRNA | 5.78% |
| Seagen | SGEN | 5.52% |
| IQVIA Holdings | IQV | 4.88% |
| Biogen | BIIB | 4.69% |
| ICON plc | ICLR | 4.33% |
| Illumina | ILMN | 4.22% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 20, 2021 | $0.3972 | Dec 27, 2021 |
| Dec 21, 2020 | $0.6079 | Dec 28, 2020 |
| Dec 23, 2019 | $0.4724 | Dec 30, 2019 |
| Dec 20, 2018 | $0.551 | Dec 27, 2018 |
| Dec 18, 2017 | $0.683 | Dec 22, 2017 |
| Dec 19, 2016 | $0.327 | Dec 23, 2016 |
News
Basic Could Be Beautiful When Biotech Bounces Back
Biotechnology stocks and exchange traded funds are into a second year of disappointing investors, but that condition won't be permanent. With that in mind, investors evaluating ideas for a biotech resur...
Size Up SBIO as Biotech Catalysts Emerge
Biotechnology stocks and the related exchange traded funds are under pressure as growth stocks stumble this year, but interested investors have some potential positive facts to ponder. First, biotech va...
Betting on Biotech Bear Market Expiration Date
Since last year, biotechnology stocks and exchange traded funds have been among the most disappointing equity assets, wilting against the backdrop of the coronavirus pandemic and in advance of broader d...
Should You Invest in the VanEck Biotech ETF (BBH)?
Sector ETF report for BBH
Positioning for Biotech Bounceback
Biotechnology stocks and exchange traded funds have frustrated investors for over a year now, but some analysts and experts believe that this gloomy trend will end soon. Investors willing to take that b...
Biotech Stocks, ETFs Starting to Look Healthier
Amid a rebound in growth equities last week, biotech stocks and exchange traded funds got in on the act, and that could be a positive sign for a group that's long been slumbering. For example, the ALPS ...
Vaccine Stocks Lift Biotech ETFs as China Enters Lockdowns
Biotechnology sector-related exchange traded funds gained on Monday, with Moderna Inc. (NasdaqGS: MRN) sitting among the top performers in the S&P 500, on renewed COVID-19 concerns as China implements l...
SBIO Is a Good Place to Be for Biotech Innovation
While biotechnology stocks and exchange traded funds continue frustrating market participants in the early innings of 2022, investors should not lose sight of the fact this corner of the healthcare sect...
How Are Biotech ETFs Reacting to These Q4 Earnings Releases?
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Biotech ETFs Muddled Despite Amgen Strength
Biotechnology sector-specific exchange traded funds were flat after Amgen (NasdaqGS: AMGN) provided a mixed earnings report but announced that it will return value to investors through greater share buy...
Omicron Vaccines to Hit Market Soon? ETF Areas to Benefit
Pfizer is likely to launch Omicron vaccine in March while Moderna is working on a booster that targets the omicron variant of Covid-19.
Biotech M&A Could Finally Perk Up in 2022
Broadly speaking, mergers and acquisitions in the healthcare sector were steady in 2021, but for many investors, there weren't enough aimed at smaller biotechnology companies. As is often the case, mark...
VanEck Announces Yearend Distributions for VanEck Equity ETFs
NEW YORK--(BUSINESS WIRE)--VanEck announced today the following 2021 annual distributions per share for its VanEck® equity exchange-traded funds
Bet on BBH for Biotechnology Bounce Back
Biotechnology equities are lagging the healthcare sector and the broader market this year, but with new variants of the coronavirus expected to continue popping up in 2022, it's impossible to ignore bio...
Smaller Biotech Stocks Ready to Perk Up
If there's an asset class that's looking forward to 2022, it's small- and mid-cap (SMID) biotechnology stocks because that group dealt with a variety of headwinds this year. However, there are more reas...
Can Biotech ETFs Gain From Positive Booster Update?
In an effort to combat the coronavirus outbreak and accelerate the distribution process of extra doses in the United States, the FDA has approved the vaccine booster shots.
Take a Look at the Top-Performing Biotech ETFs YTD
The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.
Biotech Stocks Have Colds, but They Can Heal
This year hasn't been kind to biotechnology stocks and related exchange traded funds. The headwinds faced by these assets were ratcheted up last week when the Biden administration revealed plans to purs...
Biotech ETFs to Benefit From Latest Booster Update
The U.S. government's plans to make COVID-19 vaccine booster shots available from next month will likely increase the profits of vaccine makers.